Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single-center experience

作者全名："Bai, Xuesong; He, Weiyang; Yin, Hubin; Li, Xinyuan; Zhou, Xiang; Wei, Zongjie; Yu, Haitao; Gou, Xin"

作者地址："[Bai, Xuesong; He, Weiyang; Yin, Hubin; Li, Xinyuan; Zhou, Xiang; Wei, Zongjie; Yu, Haitao; Gou, Xin] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400016, Peoples R China"

通信作者："Gou, X (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400016, Peoples R China."

来源：EXPERIMENTAL AND THERAPEUTIC MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000889717800001

JCR分区：Q3

影响因子：2.7

年份：2022

卷号：24

期号：5

开始页：　

结束页：　

文献类型：Article

关键词：human epidermal growth factor receptor 2; urothelial carcinoma of the bladder; prognosis; immunohistochemistry; antibody-drug conjugate

摘要："In recent years, antibody-drug conjugate (ADC) therapy targeting human epidermal growth factor receptor 2 (HER2) has been proven to be beneficial in patients with advanced urothelial carcinoma of the bladder (UCB); however, the role of HER2 in UCB remains obscure. Thus, the present retrospective single-center study was performed to evaluate the expression of HER2 in UCB and its prognostic significance. The HER2 status of 108 patients with UCB who underwent radical cystectomy was assessed using immunohistochemistry, and its association with the recurrence and survival rates of patients was analyzed. HER2 overexpression was observed in 57.4% of the patients; this was significantly associated with higher tumor grades (P=0.006) and stages (P<0.001). Kaplan-Meier analysis suggested that patients with HER2 overexpression had a shorter 5-year overall survival rate (P=0.005) and recurrence-free survival rate (P=0.003). Multivariate Cox regression analysis indicated that HER2 overexpression was a high-risk independent predictor of UCB recurrence (hazard ratio, 3.61; 95% confidence interval, 1.07-12.18; P=0.039). On the whole, these findings demonstrate that evaluating the HER2 status may improve the prediction of cancer recurrence and may thus guide the selection of patients that will benefit the most from HER2-ADC therapies."

基金机构：　

基金资助正文：